» Articles » PMID: 34966726

The Future of Personalized Medicine in Space: From Observations to Countermeasures

Abstract

The aim of personalized medicine is to detach from a "one-size fits all approach" and improve patient health by individualization to achieve the best outcomes in disease prevention, diagnosis and treatment. Technological advances in sequencing, improved knowledge of omics, integration with bioinformatics and new testing formats, have enabled personalized medicine to become a reality. Individual variation in response to environmental factors can affect susceptibility to disease and response to treatments. Space travel exposes humans to environmental stressors that lead to physiological adaptations, from altered cell behavior to abnormal tissue responses, including immune system impairment. In the context of human space flight research, human health studies have shown a significant inter-individual variability in response to space analogue conditions. A substantial degree of variability has been noticed in response to medications (from both an efficacy and toxicity perspective) as well as in susceptibility to damage from radiation exposure and in physiological changes such as loss of bone mineral density and muscle mass in response to deconditioning. At present, personalized medicine for astronauts is limited. With the advent of longer duration missions beyond low Earth orbit, it is imperative that space agencies adopt a personalized strategy for each astronaut, starting from pre-emptive personalized pre-clinical approaches through to individualized countermeasures to minimize harmful physiological changes and find targeted treatment for disease. Advances in space medicine can also be translated to terrestrial applications, and vice versa. This review places the astronaut at the center of personalized medicine, will appraise existing evidence and future preclinical tools as well as clinical, ethical and legal considerations for future space travel.

Citing Articles

Pharmacological Innovations in Space: Challenges and Future Perspectives.

Aksoyalp Z, Temel A, Karpuz M Pharm Res. 2024; 41(11):2095-2120.

PMID: 39532779 DOI: 10.1007/s11095-024-03788-x.


"Monitoring inflammatory, immune system mediators, and mitochondrial changes related to brain metabolism during space flight".

Tocci D, Ducai T, Stoute C, Hopkins G, Sabbir M, Beheshti A Front Immunol. 2024; 15():1422864.

PMID: 39411717 PMC: 11473291. DOI: 10.3389/fimmu.2024.1422864.


Effects of simulated space conditions on CD4+ T cells: a multi modal analysis.

Miranda S, Vermeesen R, Janssen A, Rehnberg E, Etlioglu E, Baatout S Front Immunol. 2024; 15:1443936.

PMID: 39286254 PMC: 11402665. DOI: 10.3389/fimmu.2024.1443936.


Protective alleles and precision healthcare in crewed spaceflight.

Rutter L, MacKay M, Cope H, Szewczyk N, Kim J, Overbey E Nat Commun. 2024; 15(1):6158.

PMID: 39039045 PMC: 11263583. DOI: 10.1038/s41467-024-49423-6.


Synergistic interplay between radiation and microgravity in spaceflight-related immunological health risks.

Wadhwa A, Moreno-Villanueva M, Crucian B, Wu H Immun Ageing. 2024; 21(1):50.

PMID: 39033285 PMC: 11264846. DOI: 10.1186/s12979-024-00449-w.


References
1.
Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

2.
Stark H, Willhauck M, Mirancea N, Boehnke K, Nord I, Breitkreutz D . Authentic fibroblast matrix in dermal equivalents normalises epidermal histogenesis and dermoepidermal junction in organotypic co-culture. Eur J Cell Biol. 2005; 83(11-12):631-45. DOI: 10.1078/0171-9335-00435. View

3.
Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pesic V, Molden E . Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020; 78(3):270-280. PMC: 7702196. DOI: 10.1001/jamapsychiatry.2020.3643. View

4.
Ahlfors J, Billiar K . Biomechanical and biochemical characteristics of a human fibroblast-produced and remodeled matrix. Biomaterials. 2007; 28(13):2183-91. DOI: 10.1016/j.biomaterials.2006.12.030. View

5.
Ohlsson C, Nigro G, Gomperts Boneca I, Backhed F, Sansonetti P, Sjogren K . Regulation of bone mass by the gut microbiota is dependent on NOD1 and NOD2 signaling. Cell Immunol. 2017; 317:55-58. DOI: 10.1016/j.cellimm.2017.05.003. View